Drug Profile
Alitretinoin oral - Ligand Pharmaceuticals
Alternative Names: 9-cis Retinoic acid - oral; ALRT - oral; LG 1057 - oral; LGD 1057 - oral; LGN 1057 - oralLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute promyelocytic leukaemia; Cancer; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Preleukaemia; Prostate cancer; Psoriasis; Renal cancer; Retinal disorders
Most Recent Events
- 11 Sep 2003 No development reported - Phase-II for Cancer in European Union (PO)
- 11 Sep 2003 No development reported - Phase-II for Head and neck cancer in USA (PO)
- 11 Sep 2003 No development reported - Phase-II for Ovarian cancer in USA (PO)